Chimerix, Inc. Forecasted to Post Q3 2022 Earnings of ($0.26) Per Share (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRXGet Rating) – Capital One Financial issued their Q3 2022 earnings estimates for shares of Chimerix in a report released on Wednesday, September 7th. Capital One Financial analyst N. Quibria expects that the biopharmaceutical company will earn ($0.26) per share for the quarter. Capital One Financial currently has a “Overweight” rating and a $7.00 target price on the stock. The consensus estimate for Chimerix’s current full-year earnings is $1.86 per share. Capital One Financial also issued estimates for Chimerix’s Q4 2022 earnings at $2.44 EPS, FY2022 earnings at $2.00 EPS, Q1 2023 earnings at ($0.30) EPS, Q2 2023 earnings at ($0.32) EPS, Q3 2023 earnings at ($0.31) EPS, Q4 2023 earnings at ($0.02) EPS, FY2023 earnings at ($0.95) EPS, FY2024 earnings at ($0.92) EPS, FY2025 earnings at ($0.91) EPS and FY2026 earnings at ($0.74) EPS.

Chimerix (NASDAQ:CMRXGet Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Chimerix had a negative net margin of 17,482.40% and a negative return on equity of 171.05%. The business had revenue of $0.44 million during the quarter.

CMRX has been the subject of a number of other research reports. StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Friday, May 27th. Cowen cut their price objective on shares of Chimerix to $10.00 and set a “na” rating for the company in a research note on Tuesday, May 17th. HC Wainwright dropped their price target on shares of Chimerix from $24.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 16th. Wedbush reissued an “outperform” rating on shares of Chimerix in a research report on Monday, May 16th. Finally, Maxim Group dropped their price target on shares of Chimerix to $6.00 and set a “na” rating for the company in a research report on Tuesday, May 17th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Chimerix has an average rating of “Moderate Buy” and a consensus price target of $9.60.

Chimerix Price Performance

Shares of Chimerix stock opened at $2.38 on Friday. Chimerix has a 52-week low of $1.27 and a 52-week high of $7.42. The stock has a market capitalization of $208.54 million, a price-to-earnings ratio of -1.97 and a beta of 1.15. The company has a fifty day moving average of $2.31 and a 200-day moving average of $3.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.00 and a current ratio of 2.18.

Institutional Investors Weigh In On Chimerix

Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in shares of Chimerix in the 2nd quarter worth about $30,000. Principal Financial Group Inc. lifted its position in shares of Chimerix by 77.1% in the 2nd quarter. Principal Financial Group Inc. now owns 20,007 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 8,710 shares during the period. Walleye Trading LLC purchased a new stake in shares of Chimerix in the 2nd quarter worth about $45,000. Engineers Gate Manager LP purchased a new stake in shares of Chimerix in the 1st quarter worth about $54,000. Finally, E Fund Management Co. Ltd. purchased a new stake in shares of Chimerix in the 1st quarter worth about $59,000. 63.43% of the stock is owned by hedge funds and other institutional investors.

Chimerix Company Profile

(Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Read More

Earnings History and Estimates for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.